Serina Therapeutics, Inc. Adjustments to Additional Paid in Capital, Other
Serina Therapeutics, Inc. (SER) reported Adjustments to Additional Paid in Capital, Other of -$18.50 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2024-08-09
- Serina Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2023-06-30 was $353.00K, a 52.93% decline year-over-year.
- Serina Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2023-03-31 was $526.00K, a 79.57% decline year-over-year.
- Serina Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2023 was $879.00K, a 78.81% decline from fiscal 2022.
- Serina Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2022 was $4.15M.
- Serina Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2017 was $13.22M.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|
| 2024-06-30 | -$18.50M 10-Q · filed 2024-08-09 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $0.00 derived: sum of 2 quarters · filed 2024-03-22 | $353.00K derived: sum of 3 quarters · filed 2024-03-22 | $879.00K 10-K · filed 2024-03-22 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $353.00K derived: sum of 2 quarters · filed 2023-11-14 | $879.00K 10-Q · filed 2023-11-14 | $1.36M derived: sum of 4 quarters · filed 2024-03-22 |
| 2023-06-30 | $353.00K 10-Q · filed 2023-08-14 | $879.00K 10-Q · filed 2023-08-14 | $1.36M derived: sum of 3 quarters · filed 2024-03-22 | $1.70M derived: sum of 4 quarters · filed 2024-03-22 |
| 2023-03-31 | $526.00K 10-Q · filed 2023-05-12 | $1.01M derived: sum of 2 quarters · filed 2024-03-22 | $1.35M derived: sum of 3 quarters · filed 2024-03-22 | $2.10M derived: sum of 4 quarters · filed 2024-03-22 |
| 2022-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $823.00K derived: sum of 2 quarters · filed 2024-03-22 | $1.57M derived: sum of 3 quarters · filed 2024-03-22 | $4.15M 10-K · filed 2024-03-22 |
| 2022-09-30 | $341.00K 10-Q · filed 2023-11-14 | $1.09M derived: sum of 2 quarters · filed 2023-11-14 | $3.67M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $750.00K 10-Q · filed 2023-08-14 | $3.33M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $2.58M 10-Q · filed 2023-05-12 | |||
| 2017-12-31 | $13.22M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |